Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE: RSVpreF Maternal Immunization Phase 3 Trial
NCT04424316Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 18
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus lower respiratory tract infection, sponsored by Pfizer. Started Jun 2020; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on NCT04424316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424316.